NVIDIA Corporation (NVDA.US) is discussing potential cooperation with South Korean AI chip design company Rebellions, which may include technological collaboration, investment, or even an acquisition, Bloomberg, citing sources, reported.

NVIDIA CEO Jensen Huang reportedly met Rebellions co-founder and CEO Sunghyun Park in California this week and discussed potential partnership opportunities.

Previously, Rebellions had raised approximately USD850 million from investors including SK Hynix, Samsung Venture Investment and Arm Holdings plc (ARM.US). Its latest valuation was approximately USD2.3 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

BEIJING, Aug. 21, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion" or "the Company"; 1157.HK) is showcasing its embodied intelligence technologies and robotic products for industrial applications at the 2026 World Robot Conference (WRC), taking place from Aug. 19-23, 2026, in Beijing, China.

Since 2015, the WRC has brought together companies, researchers and industry stakeholders to showcase advances in robotics and practical applications. The 2026 edition focuses on human-robot collaboration and closer alignment between technology development and industrial demand.

A Showcase for Zoomlion's Embodied Intelligence Systems

At the WRC, Zoomlion is presenting the bipedal humanoid robot Z01, the wheeled humanoid robot Z03, and the quadrupedal robot dogs D15 and D40, as well as its self-developed joint modules.

These robotic products reflect Zoomlion's application of embodied intelligence to address practical manufacturing pain points such as flexible sorting, precision assembly and wire-harness handling, with each robot configured for the requirements of its assigned task.

Zoomlion's booth features Robot Ops, an embodied intelligence operating system that debuted at Hannover Messe in April 2026. Designed as a professional development platform for embodied intelligence in the Software 3.0 era, Robot Ops integrates four core modules: basic tools, imitation learning, reinforcement learning and task orchestration. It supports a closed-loop development lifecycle covering data collection, model training, simulation and validation, as well as deployment and operations.

The platform is designed to support applications involving humanoid robots, industrial robots, construction machinery and autonomous driving, empowering industries through a single integrated platform while providing a standardized and replicable engineering pathway for the large-scale deployment of embodied intelligence.

Alongside Robot Ops, Zoomlion is also presenting ZBrain, an embodied intelligence system which enables traditional industrial robots to move beyond fixed-program execution and become intelligent operating units capable of sensing their environment, understanding tasks, making autonomous decisions and executing closed-loop operations.

Empowered by ZBrain, users can issue task instructions, after which the system autonomously performs detection, planning, execution and verification. It is designed to support high-mix, low-volume production, significantly shortening deployment timelines, accelerating changeover cycles and lowering the barrier to adoption.

At the conference, Zoomlion is highlighting capabilities that are grounded in real-world testing. Zoomlion has validated its robots across nearly 20 manufacturing scenarios at Zoomlion Smart City, where they have been deployed in active manufacturing environments. This operational experience provides the data and know-how needed to move intelligent technologies and robotic products toward large-scale industrial deployment.

Industrial and Interactive Demonstrations

Visitors can experience the capabilities of Zoomlion's robots firsthand through a series of industrial and interactive demonstrations. The Z03 performs material picking, sorts irregularly shaped items and completes the preassembly of rearview mirrors, while the Z01 handles and organizes wire harnesses. The demonstrations also include synchronized dance performances, robot-guided tours and gesture-based interactions with Z01.

The Company is advancing embodied intelligence from laboratory research to deployable industrial applications and supporting intelligent manufacturing across industries.

Visitors to the WRC 2026 can find Zoomlion at Booth D403 in Hall D.

上海2026年8月21日 /美通社/ -- 三生製藥（01530.HK）今日發佈2026年中期業績公告。今年上半年，公司實現營業收入45.3億元，同比增長3.9%，歸母淨利潤11.5億元，經調整的經營性歸母淨利潤14.4億元，同比增長26.5%，研發費用6.8億元，同比增長24.9%，公司財務資源194億元，充裕的資金儲備為研發投入和戰略佈局提供了堅實保障。上半年核心品種獲全球23個國家上市許可，海外產品銷售同比增長43%，來源於公司rhEPO、益賽普、rhTPO等品種在全球多個新興經濟體國家提升市場滲透率。

2026年以來，公司3款I類創新藥獲批上市，5款產品進入NDA階段，構建多領域創新管線矩陣，全球化競爭力與核心治療領域優勢進一步夯實。公司在全球合作、創新研發和產品商業化等方面均取得重要進展，高質量發展的步伐穩健有力。

一、PF-08634404(SSGJ-707)全球多中心多項臨床同步開展

PF-08634404(SSGJ-707)是三生製藥自主研發的PD-1/VEGF雙特異性抗體，被視為極具潛力的下一代腫瘤免疫治療產品。2025年，三生製藥授予輝瑞SSGJ-707全球開發與商業化權利，交易總額最高超60億美元，公司同時享有基於全球累計收入的梯度雙位數分成。其中14億美元首付款及1億美元股權合作，一舉刷新中國創新藥單筆出海授權交易的首付款紀錄。全球臨床試驗啟動觸發研發里程碑付款，報告期內公司已確認BD項目相關收入8.5億元。

2026年，輝瑞全力推進SSGJ-707全球多中心臨床開發，已開展9項全球多中心臨床試驗，覆蓋鱗狀/非鱗狀非小細胞肺癌、轉移性結直腸癌、廣泛期小細胞肺癌、胃食管癌、肝細胞癌、轉移性尿路上皮癌、腎細胞癌等多個高發癌種，其中2項已進入III期臨床，3項處於II期，4項處於I期。截至8月19日，SSGJ-707已註冊11項臨床，啟動1361家臨床中心，預計入組患者5016人，覆蓋全球23個國家及地區，其中中國75家醫療機構參與9項臨床方案，數量僅次於美國，位居全球第二；2026年開展的III期臨床覆蓋美國目標患者人群達22.5萬人，為其後續商業化價值奠定了堅實的患者基礎。未來，還將持續拓展該品種更多適應症及聯用治療方案，充分釋放這一核心創新品種的全球臨床價值與商業增長空間。

二、創新價值密集兌現，構建新增長引擎

2026年上半年，三生製藥創新管線進入密集收穫期。3款I類創新藥接連上市、5款產品進入NDA階段，創新動能正加速轉化為業績驅動力。

3款自主研發I類生物創新藥獲批上市。 益賽拓^®（安沐奇塔單抗）於2月獲批上市，用於治療適合系統治療或光療的中度至重度斑塊狀銀屑病成人患者。益賽拓^®具有皮損清除能力強且起效快、免疫原性低、安全性和耐受性良好、給藥便捷性高等核心優勢，有望重塑銀屑病治療預期。未來，隨著新適應症開發的持續推進，該產品將有望進一步拓寬在自免領域的臨床應用前景。

新比澳^®(羅賽促紅素α注射液)於3月獲批上市，為首個國產長效重組EPO類雙周制劑，用於治療慢性腎病（CKD）貧血的血液透析患者。產品擁有120小時超長半衰期、免疫原性低，靜脈給藥更適合血透患者，「兩週一次」的給藥方案顯著提升患者治療便利性。

益賽那^®(安弗利奇塔單抗注射液) 於8月獲批上市，為國產首個自研IgG1/κ型人源化抗IL-1β單克隆抗體，用於治療成人急性痛風性關節炎。該產品具有快速鎮痛、長效防復發、安全性優異的差異化臨床價值，是傳統激素療法的優選替代方案，痛風精準抗炎新選擇。

5款NDA階段產品蓄勢待發。 公司在NDA階段已形成5款產品的儲備梯隊，覆蓋特應性皮炎、眼科疾病、乳腺癌、減重等多個治療領域。其中， 611（抗IL-4Rα單抗）用於成人中重度特應性皮炎、601A（抗VEGF單抗）用於視網膜分支靜脈阻塞（BRVO）所致黃斑水腫，上市申請均已獲受理；合作引進的柏瑞素^®（口服紫杉醇溶液）用於HER2陰性乳腺癌、DB-1303（HER2 ADC）用於HER2陽性乳腺癌、WS2403（GLP-1受體激動劑）用於成人超重/肥胖長期體重管理，也已進入NDA階段，後續有望陸續獲批上市，為公司持續增長提供充足的產品儲備。

三、構建多領域創新管線矩陣，築牢長遠核心競爭優勢

公司在研管線持續豐富，共有25款重點在研品種，覆蓋血液腫瘤、自免、腎科、皮膚及減重等核心治療領域。腫瘤血液科：雙抗/融合蛋白多點佈局，打造差異化競爭優勢。特比澳^®（重組人促血小板生成素注射液）治療慢性肝病引起的血小板減少(CLDT)已獲美國FDA批准開展全球多中心橋接臨床。705（抗PD1/HER2雙抗）治療HER2陽性實體瘤已進入II期臨床，為國內唯一積極推進臨床的同靶點藥物，差異化優勢顯著。706（抗PD1/PDL1雙抗）治療晚期非小細胞肺癌、晚期胃腸道腫瘤已進入II期臨床。708（抗PD1/TGFβ雙抗）、709（抗PD1/LAG3雙抗）、SPGL008（抗B7H3抗體/IL-15融合蛋白）治療實體瘤，均處於I期臨床階段。SSS57（長效ActRIIB-Ig Trap融合蛋白）治療血液疾病獲批美國IND，是國內首個進入臨床的創新偏向型雙抗。腫瘤血液科管線梯隊持續完善，為長期增長儲備優質標的。腎科：聚焦核心需求，前沿靶點佈局國內首創。 SSS55（C3b雙功能融合蛋白）治療陣發性睡眠性血紅蛋白尿症(PNH)、補體相關腎病、牙周炎已進入I期臨床，具有Best-In-Class的潛力。SSS68（長效抗APRIL/BAFF雙抗）治療IgA腎病，中美IND雙獲批，為國內唯一進入臨床的長效雙抗。皮膚及減重：賽道拓新、管線延伸。WS204（柯拉特龍乳膏劑）治療中重度尋常性痤瘡處於III期臨床。SSS67（抗ActRIIA/ActRIIB雙抗）治療超重/肥胖症已進入I期臨床。 自身免疫：多款產品進入關鍵臨床階段，研發進度國內領先。 益賽拓^®（安沐奇塔單抗注射液）強直性脊柱炎III期臨床已完成全部受試者入組，放射學陰性中軸型脊柱炎III期臨床已完成首例受試者入組。

益賽那^®（安弗利奇塔單抗注射液）痛風性關節炎間歇期適應症多次給藥的劑量探索II期研究已啟動。

610（抗IL-5單抗）成人重度嗜酸性粒細胞哮喘（EA）III期臨床已完成全部受試者入組，青少年重度EA的III期臨床入組中。611（卡泰奇拜單抗）成人中重度特應性皮炎已遞交NDA並獲受理。626（抗BDCA2單抗）系統性紅斑狼瘡和皮膚型紅斑狼瘡II期臨床啟動中；627（抗TL1A單抗）潰瘍性結腸炎II期已啟動入組；716（OX40L/IL-31RA雙抗）特應性皮炎已獲批中美IND，I期臨床已啟動入組。早研管線全方位覆蓋自免適應症，其中717（CD3/BCMA/CD19人源化三特異性抗體）用於系統性紅斑狼瘡/狼瘡性腎炎/類風濕關節炎，718（抗TL1A/IL-23雙特異性抗體注射液）用於炎症性腸病（潰瘍性結腸炎/克羅恩病），719（抗TSLP/IL-4R雙特異性抗體吸入劑）用於哮喘/慢性阻塞性肺疾病，629（IL-23R口服多肽）用於銀屑病/炎症性腸病，均已進入IND或臨床前研究階段，展現出公司在自免領域前瞻性的全鏈條佈局。 

四、ESG治理獲權威認可，彰顯可持續發展實力

一直以來，公司將環境、社會及治理（ESG）理念深度融入經營管理全流程，持續完善治理架構、踐行社會責任、推進綠色運營，可持續發展建設取得紮實成效，收穫多方權威平台的肯定。2026年7月，公司在萬得(Wind) ESG評級躍升至AA級，躋身生物科技行業前3.2%，充分印證公司在風險管理、合規運營、社會責任實踐等維度的綜合實力。與此同時，公司落地的公益項目再度獲評 「中國醫藥工業企業社會責任優秀案例」，這也是行業層面對企業投身公益事業、履行企業社會責任的認可。

三生製藥董事局主席兼首席執行官婁競博士表示：「2026年初，生物醫藥被列為國家新興支柱產業，產業持續提質升級，新藥研發能力為企業發展提供持續動能。立足三十餘年產業積澱，我們堅持守正創新，持續加大研發投入，深耕腫瘤、自免、腎科等領域，持續優化研發管線，加強人才梯隊建設。今年上半年，公司多款重點創新藥集中獲批，拓展了未來發展的空間。接下來，我們將持續推進後期管線的上市進程，讓更多具備臨床價值的創新藥服務廣大患者。」

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso's proprietary bispecific antibodies ivonescimab and cadonilimab is also planned.

AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.

B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target.

AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies.

Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating treatment standards for major cancers worldwide and building a broad oncology portfolio to create next-generation standard of care.

In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.

About AK157D1

AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. It comprises a recombinant humanized IgG1/κ monoclonal antibody site-specifically conjugated to Dxd, a camptothecin-derived topoisomerase I inhibitor, via a maleimidocaproyl-alanine-alanine-alanine (MC-AAA) linker to interchain cysteine residues. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- NagaCorp Ltd. ("NagaCorp" or the "Company", SEHK Stock Code: 3918), together with its subsidiary NagaWorld, a leading Integrated Resort in the Mekong Region, is pleased to announce the continuation of the Great Place To Work^® Certification^™ for another consecutive year. NagaWorld achieved an exceptional Trust Index^™ score of 97%, up from 95% last year and well above the industry standard of 65%. The stronger results reflect a workplace built on trust, respect, and genuine employee engagement — qualities that are especially significant in the hospitality sector, where employee experience translates directly into guest experience and business performance. This recognition is earned through the voices of employees themselves, and is guided by the Company's CARES values of Collaboration, Accountability, Respect, Excellence, and Sustainability, which continue to underpin an inclusive workplace culture where diversity of background and perspective is valued, and equal opportunity is upheld as a fundamental principle.

The Company remains committed to investing in its people through learning, career development, and leadership opportunities. Employee feedback is not only measured but acted upon, reinforcing the Group's position as an employer of choice for individuals seeking to build meaningful careers. While this certification marks a proud milestone, the Company regards it as part of a continuous journey towards an even better workplace — one that belongs to every employee whose passion, collaboration, and commitment make the organisation exceptional.

"NagaWorld's growth in workplace culture and excellence has been best demonstrated by our own Naga family members who show up each day with an earnestness for personal growth and have an inherent sincerity in practising local hospitality and culture in our service offerings," said Mr. Chen Yiy Fon, Chief Executive Officer and Executive Director of NagaCorp. "I am proud of each one of our members and congratulate you on achieving the Great Place To Work^® Certification^™ for a second year. Ours is a workplace culture that each of you has helped build, centred around trust and respect, not just performance targets. We also thank the Great Place To Work^® organisation for recognising and featuring the growth taking place in Cambodia. As NagaWorld continues to grow and evolve our determination to improve with our people will not change. We will continue to invest in human resource best practices, continue to listen to feedback, and keep building a workplace of excellence and mutual respect that will fundamentally help us make a difference in the communities we operate in and contribute to in this fast-emerging economy."

This achievement further underscores the success of the Company's Sustainability and Corporate Social Responsibility (SCSR) initiatives, ensuring that employees are not only empowered and rewarded, but also active participants in creating a positive impact on the wider community. Reinforcing its continued progress in sustainability leadership, NagaCorp's inaugural inclusion in the FTSE4Good Index Series marks a significant milestone in its ESG journey, reflecting enhanced ESG practices, strengthened sustainability governance, and the embedding of responsible business considerations across its operations. Together, these accomplishments highlight NagaCorp's dedication to advancing its SCSR goals and delivering tangible, sustained value for employees, communities, and the environment.

Key SCSR achievements driving this year's higher certification score and demonstrating continued progress include:

• Turning Awareness into Action for a Cleaner, Greener Cambodia — Advancing environmental sustainability and community education through the "An Ocean of Plastic" exhibition, the Clean and Green School Programme, and the Green Cambodia: Tree Planting Programme, engaging 79 schools, delivering 40 environmental workshops, collecting 5 tonnes of plastic for recycling, and raising school cleanliness standards from 55% to 96%. Since 2014, more than 32,000 saplings have been planted, while 62,500 tree seedlings were distributed in 2026 alone.
  
  
• Empowering Employees, Creating Community Impact — The Impact Initiator Programme inspires employees to lead community initiatives spanning education, student welfare, school infrastructure, and sustainability, from digital literacy and enrichment programmes to school materials, improved learning environments, and community vegetable gardens, turning employee-led ideas into tangible impact while building leadership capabilities.
  
  
• Holistic Employee Well-being and Engagement — Employee welfare is supported through fitness, wellness, and community events, including growing participation in the Women Run 10K and Phnom Penh International Half Marathon, as well as the Company-hosted NagaRun and Earth Hour 5K Fun Run. The expansion of NagaMart, alongside live cooking demonstrations promoting healthy eating, further supports employees' everyday well-being.
  
  
• Fostering Diversity, Equity, and Inclusion — The Company is committed to a vibrant, inclusive workplace underpinned by equal opportunity and fair treatment, actively nurturing local talent and advancing women's leadership. Women represent 49.9% of the total workforce and 33% of managerial positions, reflecting continued progress towards a balanced and inclusive organisation.

NagaCorp remains committed to integrating sustainability and responsible business practices into its long-term strategy, recognising that sustainable performance is driven by strong governance, engaged employees, and meaningful community impact. Collectively, these achievements reinforce the Company's commitment to "Shaping Tomorrow, Together" and to delivering sustainable, long-term value for all stakeholders.

ABOUT NAGACORP LTD. 
NagaCorp Ltd. has been listed on The Hong Kong Stock Exchange since October 2006 (SEHK stock code: 3918). Established in 1995, NagaCorp's wholly owned subsidiary NagaWorld Ltd. owns, manages and operates the only world-class integrated entertainment and leisure complex in Phnom Penh, the capital of the Kingdom of Cambodia. It owns a casino licence valid for 70 years, and exclusive gaming rights for a period of 51 years (1995-2045). NagaCorp was selected for inclusion in the Hang Seng Foreign Companies Composite Index launched on 5 September 2011. On 10 September 2018, the Group was included as a constituent of the Hang Seng Composite Large Cap & Mid Cap Index.  On 13 March 2023, the Group was listed as one of the eligible securities for Southbound Trading under Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.

Learn more at nagacorp.com and follow NagaCorp on LinkedIn.

ABOUT NAGAWORLD LIMITED
Since our opening in 1995, NagaWorld has been at the forefront in the development of Cambodia's dynamic tourism industry, working closely with various governmental stakeholders. As one of the nation's largest private employers in the hospitality sector, we have over the years trained numerous employees in world-class service standards who have since moved on to further contribute to the vibrant hospitality sector in Cambodia. At NagaWorld, we believe that building a great workplace is not only about business performance but also about shaping a sustainable future for our employees, our guests, and the communities we serve.

Learn more at nagaworld.com and follow NagaWorld on LinkedIn, Facebook and Instagram.

About Great Place To Work^® Certification^™
Great Place To Work^® Certification^™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place To Work Certification is recognised worldwide by employees and employers alike and is the global benchmark for identifying and recognising outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

ABOUT GREAT PLACE TO WORK^®
As the global authority on workplace culture, Great Place To Work^® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.

Learn more at greatplacetowork.com and follow Great Place To Work^® on LinkedIn, X, Facebook and Instagram.

香港2026年8月21日 /美通社/ -- 金界控股有限公司（「金界控股」或「本公司」，港交所股份代號：3918）連同其附屬公司、湄公河區域領先的綜合式娛樂度假村金界娛樂城，欣然宣佈連續第二年榮獲Great Place To Work^®認證™。金界娛樂城今年取得卓越的信任指數™評分97%，較去年的95%進一步提升，並遠高於65%的行業標準。此項佳績反映公司成功建立了以信任、尊重及員工真誠參與為基礎的工作環境；在酒店及旅遊業中，員工體驗尤具意義，因為這會直接影響賓客體驗及業務表現。這項認可完全源自員工的真實心聲，並由本公司的CARES核心價值觀 — 協作（Collaboration）、問責（Accountability）、尊重（Respect）、卓越（Excellence）及可持續發展（Sustainability） — 所引領，持續鞏固共融的職場文化，重視不同背景及觀點的多元性，並將平等機會奉為基本原則。

本公司一直致力透過學習、職業發展及領導力機會，投放資源培育人才。員工意見不僅受到重視，更會化為實際行動，進一步鞏固集團作為理想僱主的地位，吸引有志建立具意義事業的人才加入。儘管此項認證標誌著公司值得自豪的重要里程碑，本公司亦視之為持續邁向更佳職場的旅程之一，而這個職場屬於每一位憑藉熱誠、協作及承諾鑄就企業卓越表現的員工。

金界控股行政總裁兼執行董事曾羽鋒先生表示：「金界娛樂城在職場文化及卓越表現方面的成長，最能體現在我們每一位金界大家庭成員身上。他們每天以追求個人成長的真誠態度投入工作，並將本地待客之道及文化真摯地融入我們的服務當中。我為每一位成員感到自豪，並恭賀大家連續第二年榮獲Great Place To Work^®認證™。我們的職場文化由各位共同建立，以信任與尊重為核心，而不僅僅是績效目標。我們亦感謝Great Place To Work^®對金界娛樂城的認可，並向國際社會展示柬埔寨正在持續取得的發展成果。隨着金界娛樂城持續成長及發展，我們與員工共同進步的決心絕不動搖。我們將繼續投資於人力資源最佳實踐，持續傾聽員工意見，並不斷打造卓越及相互尊重的職場，從根本上協助我們為營運所在及所貢獻的社區帶來改變，並為這個快速崛起的經濟體作出貢獻。」

此項成就進一步彰顯本公司可持續發展及企業社會責任（SCSR）舉措的成功，確保員工不僅獲得賦權及回報，亦積極參與為更廣泛社區創造正面影響。隨着金界控股在可持續發展領導力方面持續取得進展，公司首次獲納入富時羅素社會責任指數系列（FTSE4Good Index Series），標誌其ESG發展進程的重要里程碑，反映公司在ESG實踐、可持續發展管治，以及在營運各環節全面落實負責任營商考量方面均有所提升。上述成就共同彰顯金界控股致力推進SCSR目標，並為員工、社區及環境帶來實質且長遠價值的承諾。

推動今年認證評分進一步提升並展示持續進展的主要SCSR成果包括：

• 將環保意識轉化為行動，共建更潔淨、更綠色的柬埔寨 — 透過「An Ocean of Plastic」展覽、「潔淨綠色校園計劃」及「綠色柬埔寨：植樹計劃」推進環境可持續發展及社區教育，吸引79所學校參與，舉辦40場環保工作坊，收集5噸塑膠作回收，並將校園清潔標準由55%提升至96%。自2014年以來已種植逾32,000棵樹苗，單在2026年便額外派發了62,500棵樹苗。

• 賦能員工，創造社區影響力 —  「影響力發起人計劃」（Impact Initiator Programme）鼓勵員工主導涵蓋教育、學生福祉、校園基建及可持續發展的社區項目，包括數碼素養及增益課程、學校物資支援、學習環境改善及社區菜園等，將員工主導的構思轉化為實質影響，同時培育領導能力。

• 全方位員工福祉及參與 — 公司透過健身、健康及社區活動支持員工福祉，包括參與Women Run 10K及金邊國際半程馬拉松的員工人數不斷增加，以及由公司主辦的NagaRun及 「地球一小時」五公里歡樂跑（Earth Hour 5K Fun Run）。NagaMart的擴展，加上推廣健康飲食的現場烹飪示範，進一步支持員工的日常福祉。

• 促進多元、公平及共融 — 本公司致力打造充滿活力且共融的職場，堅守平等機會與公平待遇原則，積極培育本地人才並推動女性領導力。女性佔員工總數49.9%，並佔管理職位33%，反映公司在建立均衡及共融組織方面持續取得進展。

金界控股將繼續把可持續發展及負責任營商實踐融入其長遠策略，深信可持續表現建基於穩健管治、高度投入的員工及具意義的社區影響力。上述成就共同鞏固本公司「共創明天」（Shaping Tomorrow, Together）的承諾，並為所有持份者創造可持續的長遠價值。

關於金界控股有限公司
金界控股有限公司於二零零六年十月在香港聯合交易所上市（港交所股份代號︰3918）。金界控股的全資附屬公司NagaWorld Ltd.成立於一九九五年，擁有、管理並經營柬埔寨王國首都金邊市唯一的一座世界級綜合娛樂及休閒綜合設施，持有為期70年的賭場牌照，並擁有為期51年的賭場獨家經營權（一九九五年至二零四五年）。金界控股有限公司獲納入於二零一一年九月五日推出的恒生外國公司綜合指數及恒生環球綜合指數。於二零一八年九月十日，本集團獲納入恒生綜合大中型股指數成份股。於二零二三年三月十三日，本集團被列入成爲滬港通及深港通下港股通合資格證券之一。

更多資訊，請瀏覽nagacorp.com並在LinkedIn關注金界控股。

關於NagaWorld Limited
自1995年開業以來，金界娛樂城一直走在柬埔寨旅遊業蓬勃發展的前沿，並與各政府持份者緊密合作。NagaWorld Limited作為全國酒店業最大的私營僱主之一，多年來為無數員工提供世界級服務標準培訓，他們其後亦為柬埔寨充滿活力的酒店業作進一步貢獻。在金界娛樂城，我們相信建立理想的工作場所不僅關乎業務表現，更關乎為我們的員工、賓客及所服務的社區塑造可持續的未來。

更多資訊，請瀏覽nagaworld.com並在LinkedIn、Facebook及Instagram關注金界娛樂城。

關於Great Place To Work^®認證™
Great Place To Work^®認證™是企業致力爭取、最具代表性的「理想僱主」認可。該認證完全基於員工對其職場體驗的反饋，尤其是員工是否持續感受到高度信任的工作環境。Great Place To Work認證獲全球員工及僱主廣泛認可，是識別及表彰卓越員工體驗的全球基準。每年，來自60個國家逾10,000家公司申請取得Great Place To Work認證。

關於Great Place To Work^®
作為全球職場文化的權威，Great Place To Work^®憑藉30年開創性研究及數據，協助每個地方成為適合所有人的理想工作場所。其專有平台及For All™模型協助企業評估每位員工的體驗，而模範職場獲得Great Place To Work認證™或榮登備受推崇的「最佳職場™」榜單。

更多資訊，請瀏覽greatplacetowork.com及在LinkedIn、X、Facebook及Instagram關注 Great Place To Work^®。

Innovation-driven, Steady Advancement

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the first half of 2026, Sunshine Guojian pursued its dual-engine strategy of "In-house R&D plus External Collaboration", drove growth through innovation, delivered solid performance, advanced its R&D pipeline efficiently, and secured successive approvals for multiple products, demonstrating a positive development trajectory.

Solid Growth in Performance and Continued Progress in External Collaboration

In the first half of 2026, Sunshine Guojian delivered solid performance growth, with total operating revenue reaching RMB 866 million, representing a year-on-year increase of 34.84%; net profit attributable to equity holders of the Company amounted to RMB 371 million, up 95.10% year-on-year; net profit attributable to equity holders of the Company excluding non-recurring gains and losses stood at RMB 260 million, up 65.15% year-on-year; basic earnings per share reached RMB 0.41, up 95.24% year-on-year. Sunshine Guojian continued to increase its innovative R&D investment, with R&D expenses rising 32.41% year-on-year to RMB 245 million.

Based on its strong confidence in stable operations and future growth, Sunshine Guojian proposed an interim profit distribution plan for 2026: a cash dividend of RMB 0.42 (tax inclusive) per 10 shares for the first half of 2026, with no conversion of capital reserve into share capital and no bonus share issue. This reflects Sunshine Guojian's robust cash flow and sustainable profitability foundation, while sharing its growth with shareholders.

The PF-08634404 (SSGJ-707) program, in collaboration with Pfizer, has initiated 9 global multicenter clinical trials covering multiple solid tumor indications, including non-small cell lung cancer and colorectal cancer, with the clinical development significantly accelerated. As several clinical milestones are successively achieved and overseas commercialization is subsequently realized, various clinical and regulatory milestone payments, as well as global sales revenue sharing, will continue generating returns, which is expected to bring sustained and solid cash flow to Sunshine Guojian, and further reinforce its overall financial position.

Continued Breakthroughs Across the R&D Pipeline, Poised for Milestone Realization

In the first half of 2026, Sunshine Guojian accelerated the advancement of clinical studies for its R&D programs, and achieved multiple milestone events, continuously building a new growth driver. As of the report date, Yisaituo^® (Amdokitug Injection) and Yisaina^® (Anflekitug Injection), both independently developed by Sunshine Guojian, had been approved for marketing. The approval timeline for NDA of one key new autoimmune product is clearly visible, and multiple autoimmune programs have entered the NDA submission or mid-to-late-stage clinical phases.

Yisaituo^® (Amdokitug Injection, R&D code: 608) was approved for marketing by the National Medical Products Administration (NMPA) in February 2026 for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. With core advantages including robust and rapid clearance of skin lesions, low immunogenicity, favorable safety and tolerability profile, and convenient administration, Yisaituo^® is poised to reshape psoriasis treatment expectations. Currently, two additional indications for this product, both ankylosing spondylitis and non-radiographic axial spondyloarthritis, have entered Phase III clinical studies. The product is expected to further broaden its clinical applications in autoimmune diseases as new indications are continuously developed.

Yisaina^® (Anflekitug Injection, R&D code: 613) was approved for marketing by the NMPA in August 2026 for acute flares of gouty arthritis in adult patients who are contraindicated for, intolerant of, or inadequately responsive to non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine, and those are unsuitable for repeated use of corticosteroids. As the first in-house IgG1 kappa humanized anti-IL-1β monoclonal antibody marketed in China, Yisaina^® holds broad market potential. The product demonstrates significant effects in pain relief and recurrence prevention, while maintaining a favorable safety and tolerability profile. It addresses an unmet clinical need among patients with limited response to conventional therapies, intolerance to corticosteroids or colchicine, and recurrent gout attacks.

One product's NDA has been accepted for review. The marketing application for anti-IL-4Rα mAb injection (R&D code: 611) for moderate-to-severe atopic dermatitis in adults was submitted and accepted for review in February 2026.

Sunshine Guojian continues to advance Phase III clinical trials for multiple products. Amdokitug Injection (R&D code: 608): Enrollment of all subjects in the Phase III clinical trial for ankylosing spondylitis has been completed. The first subject has been enrolled in the Phase III clinical trial for non-radiographic axial spondyloarthritis. Humanized anti-IL-5 monoclonal antibody injection (R&D code: 610): Enrollment of all subjects in the Phase III clinical trial for severe eosinophilic asthma in adults has been completed. Enrollment is ongoing in the Phase III clinical trial for severe eosinophilic asthma in adolescents. Anti-IL-4Rα mAb injection (R&D code: 611): Enrollment is ongoing in the Phase III clinical trial for chronic obstructive pulmonary disease. Enrollment of all subjects in the Phase III clinical trial for moderate-to-severe atopic dermatitis in adolescents aged 12 to 17 has been completed. The primary endpoint in the Phase III clinical trial for chronic rhinosinusitis with nasal polyps has been achieved, with significant efficacy demonstrated. The Phase III clinical trial for moderate-to-severe atopic dermatitis in children is being initiated. The interim analysis met the primary endpoint in the Phase III clinical trial evaluating combination treatment with topical corticosteroids for moderate-to-severe atopic dermatitis in adults. Anflekitug Injection (R&D code: 613): A Phase II multiple-dose dose-exploration study has been initiated for the intercritical gouty arthritis.

Early-stage clinical programs are progressing rapidly. The enrollment of all subjects in Phase Ib clinical study of recombinant humanized anti-BDCA2 monoclonal antibody injection (R&D code: 626) for systemic lupus erythematosus has been completed. Phase II clinical studies for systemic lupus erythematosus and cutaneous lupus erythematosus are being initiated. The Phase I clinical study of recombinant humanized anti-TL1A monoclonal antibody injection (R&D code: 627) for ulcerative colitis in healthy Chinese subjects via subcutaneous administration across all dose cohorts has been completed, and positive results were obtained. Enrollment in Part 1 of the Phase II clinical study for ulcerative colitis has been initiated. The IND application for OX40L/IL-31RA bispecific antibody injection (R&D code: 716) for atopic dermatitis has been approved by the NMPA and U.S. Food and Drug Administration (FDA). Enrollment of healthy Chinese subjects in a Phase I clinical study has been initiated.

Accelerated Translation of Cutting-Edge Targets, Deepening Commitment to Autoimmune Diseases

By deeply exploring the key immune pathways and regulatory nodes in disease onset and progression, and leveraging its structural biology, AI-assisted drug design, and high-throughput screening platforms, Sunshine Guojian continues to build a portfolio of next-generation high-value targets and innovative molecular formats, forming a diversified and differentiated product matrix encompassing bispecific antibodies, trispecific antibodies, oral peptides, and inhaled antibodies. Multiple innovative programs have now entered the IND or pivotal preclinical study stages, including CD3/BCMA/CD19 humanized trispecific antibody injection (R&D code: 717), recombinant anti-TL1A/IL-23 bispecific antibody injection (R&D code: 718), TSLP/IL-4R bispecific antibody inhalation (R&D code: 719), IL-23R oral peptide (R&D code: 629), among others.

Leveraging its world-class core technology platforms and innovation systems, Sunshine Guojian is moving beyond the traditional monoclonal antibody format and initiating multi-dimensional iteration of technological pathways. From discovery to development and from data to value, Sunshine Guojian is accelerating new drug R&D and enhancing clinical value. Sunshine Guojian is driving leapfrog progress in the autoimmune disease field through coordinated development of multiple products, establishing a full-cycle pipeline portfolio characterized by products that can be commercialized in the short term, provide meaningful support in the medium term, and deliver industry leadership over the long term.

Dr. Jing Lou, Chairman of the Board and Chief Executive Officer of 3S Bio Inc., and Chairman of Sunshine Guojian, stated: With Sunshine Guojian's pipeline gradually entering a harvest phase, it has established a tiered innovation portfolio consisting of mature products that fortify the operational foundation, innovative products that foster growth momentum, and cutting-edge pipelines that underpin long-term development. Supported by a commercialization platform covering nearly 4,800 medical institutions, Sunshine Guojian has established an integrated sales network encompassing hospitals, dual-channel pharmacies, specialty DTP pharmacies, and Internet hospitals. Looking ahead, Sunshine Guojian will continue to increase investment in early-stage innovative R&D, take a forward-looking approach to building an end-to-end innovation system, identify targets with clinical advantages, steadily advance the development and launch of new products, and deliver high-quality innovative biologics to more patients faster.

上海2026年8月21日 /美通社/ -- 今日，中國抗體藥先行者三生國健（證券代碼：688336.SH）發佈2026年半年度報告。報告顯示，公司在2026年上半年，踐行「自主研發+外部合作」的雙輪驅動戰略，以創新為驅動力，實現業績穩健攀升，在研管線高效推進，多款產品陸續獲批，發展態勢向好。 

業績穩中有升，對外合作持續進展

2026年上半年，三生國健業績持續向好，維持穩定增長態勢，營業總收入8.66億元，同比增長34.84%；歸屬於母公司所有者的淨利潤達到3.71億元，同比增幅95.10%；歸屬於母公司所有者的扣除非經常性損益的淨利潤為2.60億元，同比增長達65.15%；基本每股收益0.41元，同比上升高達95.24%；公司持續加大創新性研發投入，研發費用同比增長32.41%，達2.45億元。

基於對公司穩定經營及未來發展的堅定信心，公司制定了2026年半年度利潤分配方案：2026年中期擬每10股派發現金紅利人民幣0.42元（含稅），不進行資本公積轉增股本，不送紅股，體現了公司具備穩健的現金流和可持續的盈利基礎，同時與投資者共享企業發展成果。   

與輝瑞合作的PF-08634404（SSGJ-707）項目已開展9項全球多中心臨床試驗，覆蓋非小細胞肺癌、結直腸癌等多個實體瘤適應症，臨床開發全面提速。隨著各臨床里程碑節點陸續達成、後續海外商業化落地，各類臨床及註冊里程碑款項、全球銷售分成將持續兌現，預計為公司帶來持續穩定現金流，持續夯實公司整體財務穩健性。

研發管線持續突破、亟待集中兌現

2026年上半年，三生國健在研項目臨床研究推進速度加碼，迎來多個里程碑節點，持續為公司打造第二增長曲線。截至業績發佈日，公司自主研發的益賽拓®（安沐奇塔單抗注射液）、益賽那®（安弗利奇塔單抗注射液）獲批上市，1款重磅自免新品NDA兌現窗口已清晰可見，後續多個自免項目進入上市申報及臨床中後期階段。

益賽拓^®（安沐奇塔單抗注射液，研發代碼：608）於今年2月獲國家藥品監督管理局批准上市，用於治療適合系統治療或光療的中度至重度斑塊狀銀屑病成人患者。益賽拓^®具有皮損清除能力強且起效快、免疫原性低、安全性和耐受性良好、給藥便捷性高等核心優勢，有望重塑銀屑病治療預期。當前，該產品另外兩項適應症強直性脊柱炎和放射學陰性中軸型脊柱炎，均已進入III期臨床研究階段。未來，隨著新適應症開發的持續推進，該產品將有望進一步拓寬在自免領域的臨床應用前景。

益賽那^®（安弗利奇塔單抗注射液，研發代碼：613）於今年8月獲國家藥品監督管理局批准上市，用於治療對非甾體類抗炎藥和/或秋水仙鹼禁忌、不耐受或缺乏療效的以及不適合反覆使用類固醇激素的成人痛風性關節炎急性發作。益賽那^®作為國產首個自研IgG1/κ型人源化抗IL-1β單克隆抗體，具有廣闊的市場前景。該產品在疼痛改善、預防復發效果明顯並表現出良好的安全性和耐受性，填補了常規藥物療效有限、不耐受激素及秋水仙鹼、痛風反覆發作的臨床治療缺口。

1款產品上市申請已獲受理。卡泰奇拜單抗注射液（研發代碼：611）2026年2月成人中重度特應性皮炎適應症已遞交NDA並獲受理。

持續推進多個項目的III期臨床進展。安沐奇塔單抗注射液（研發代碼：608)：強直性脊柱炎適應症臨床III期完成所有受試者入組,放射學陰性中軸型脊柱炎適應症臨床III期完成首例受試者入組。抗IL-5人源化單克隆抗體注射液（研發代碼：610）：成人重度嗜酸性粒細胞哮喘適應症的III期臨床完成所有受試者入組，青少年重度嗜酸性粒細胞哮喘適應症的III期臨床入組中。卡泰奇拜單抗注射液（研發代碼：611）：慢性阻塞性肺疾病適應症臨床III期研究持續入組中，青少年（12~17歲）中重度特應性皮炎適應症的臨床III期完成所有受試者入組，慢性鼻竇炎伴鼻息肉III期研究主要終點已達成，療效顯著，兒童中重度特應性皮炎III期臨床啟動中，聯合外用糖皮質激素治療成人中重度特應性皮炎適應症的臨床III期中期分析結果達到主要終點。安弗利奇塔單抗注射液（研發代碼：613）已啟動痛風性關節炎間歇期適應症多次給藥的劑量探索II期研究。

臨床早期項目進度領先。重組抗BDCA2人源化單克隆抗體注射液（研發代碼：626）系統性紅斑狼瘡適應症臨床Ib期研究完成全部受試者入組，該適應症及皮膚型紅斑狼瘡臨床II期已在啟動中。重組抗TLIA人源化單克隆抗體注射液（研發代碼：627）潰瘍性結腸炎已完成中國健康人I期皮下注射給藥全部劑量組研究並獲得積極結果，並啟動潰瘍性結腸炎II期part 1臨床研究入組。OX40L|IL-31RA雙特異性抗體注射液（研發代碼：716）特應性皮炎適應症已經獲得中美IND的臨床試驗批件並啟動中國健康人I期臨床研究入組。

前沿靶點加速轉化，持續深耕自免賽道

三生國健通過深入挖掘疾病發生發展的關鍵免疫通路與調控節點，依托結構生物學、AI輔助藥物設計及高通量篩選平台，持續佈局新一代高價值靶點與創新分子類型，已形成雙抗、三抗、口服多肽、吸入抗體等多元化、差異化的產品矩陣。目前創新項目中已有多個進入IND或臨床前關鍵研究階段，其中包括：CD3/BCMA/CD19人源化三特異性抗體注射液（研發代碼：717）、重組抗 TL1A/IL-23雙特異性抗體注射液（研發代碼：718）、TSLP/IL-4R雙特異性抗體吸入劑（研發代碼：719）、IL-23R口服多肽（研發代碼：629）等。

三生國健依靠國際一流的核心技術平台與創新體系，打破傳統單抗形態，開啟技術路徑多維度迭代；從發現到開發，從數據到價值，加速新藥研發，提升臨床價值。推進自免領域「多產品協同」跨越式進展，打造「短期可落地、中期有支撐、長期具引領」的全週期管線佈局。

三生製藥董事局主席兼首席執行官、三生國健董事長婁競博士表示：三生國健管線逐步進入收穫期，公司已形成「成熟產品築牢經營基本盤、創新新藥培育增長動能、前沿管線儲備夯實長期發展」的梯度化創新佈局。依托廣泛覆蓋近4800家醫療機構的商業化體系，搭建起「醫院+雙通道藥房+特藥DTP+互聯網醫院」的一體化銷售網絡。未來，三生國健將持續加大早期創新研發，前瞻性佈局全鏈條創新體系，挖掘具備臨床優勢靶點，穩步提升新品開發與上市進程，推動高品質創新生物藥更快惠及更多患者。

社區共融及文化出版項目雙獲國際殊榮

澳門2026年8月20日 /美通社/ -- 金沙中國有限公司於2026年亞太旅遊協會金獎（PATA Gold Awards）中再創佳績，一舉囊括兩項金獎殊榮：分別憑《金沙中國呈獻：快樂之泉多巴胺》藝術畫冊榮獲「最佳市場推廣項目──刊物（業界）」金獎，這是繼去年雙語圖冊《芳草尋源——圖説草堆街》榮獲同一獎項後，連續第二年以出版刊物摘下該項殊榮；以及憑「金沙物美嘉年華」榮獲「可持續與共融推廣項目」金獎。兩項殊榮充分彰顯金沙中國在文化藝術及企業社會責任方面的卓越成效，持續打造高質量、多元化的非博彩項目，豐富居民及旅客體驗，並積極推動本澳文藝人才培育、中小企發展及社會共融，全力配合澳門特區政府經濟適度多元發展的施政方針，助力澳門鞏固「世界旅遊休閒中心」定位。

金沙中國有限公司行政副主席王英偉博士表示：「金沙中國今年再度榮獲亞太旅遊協會獎項，並同時獲頒兩項金獎，不僅是對公司多年積極推動非博彩發展的高度肯定，亦是對團隊不懈努力的莫大鼓舞，充分印證我們持續發揮『旅遊+』協同效益，為澳門創造長遠價值。一直以來，我們秉持真誠用心、精益求精的態度，致力將每項非博彩活動與本澳社區緊密連結，讓每份投入轉化為推動城市多元發展的力量；無論是透過文化藝術項目向國際展現澳門多元魅力，還是藉由社區關愛活動支持社群及中小企成長，我們堅持以實際行動回應澳門發展所需、與社區攜手並進。未來，金沙中國將持續攜手政府及社會各界，拓展『旅遊+』賦能城市長遠發展的更多可能，為澳門經濟適度多元發展及『世界旅遊休閒中心』建設貢獻力量。」

發揮盛事平台效應 推動澳門社區共融發展

「金沙物美嘉年華」獲頒「可持續與共融推廣項目」金獎，表彰活動多年來發揮全澳最大規模消費折扣展的平台優勢，打造兼具經濟效益與社會價值的澳門年度品牌盛事。活動於2020年疫情期間創辦，源於金沙中國與本澳社區風雨同行的信念，每年免費為本澳中小微企、社服機構及金沙零售商戶提供大型展銷平台，並結合精彩多元的娛樂及親子體驗，提升展會的多樣性及吸引力。活動至今累計提供逾4,000個展位，吸引80萬人次參與，現已發展成為深受大灣區居民及旅客歡迎的盛夏購物休閒盛事，持續助力提振本澳經濟動力。

七載耕耘，公司將「以大帶小」及「金沙關懷」關愛社區理念融入嘉年華之中，成功將一項消費盛事昇華為匯聚社區力量、促進多元共融的重要平台；每年向本澳社服機構提供展銷平台、表演機會及遊樂體驗，為本澳不同持份者創造更多共同參與、拓展營銷及接觸社群的機會。同時，活動增進公眾對社服機構工作的認識與了解，促進本澳社區的相互理解、連結與關懷。

參與嘉年華的社服機構由首屆五間增加至累計30間，規模擴展六倍，當中涵蓋社會復康、青年發展、動物權益及弱勢社群支援等領域，迄今累計惠及近1,500名服務使用者，充分體現活動在凝聚社區力量的積極成效。此外，公司社區義務工作者──金沙中國關懷大使長期支持活動，七年累計400多名義工參與服務，貢獻逾1,120小時義工時數，持續協助嘉年華的籌辦工作，並陪伴本澳弱勢社群體驗嘉年華活動，以貼心支援協助本澳社群融入社會。

作為「金沙關懷」企業公民計劃的其中一環，金沙中國關懷大使計劃自2009年成立至今累計貢獻逾362,000小時義工服務時數，持續凝聚團隊力量回饋社會，推動社區共融，彰顯金沙中國與澳門同心同行的長遠承諾。

藝術出版珍存策展成果   彰顯澳門文藝深厚實力

另一項目《金沙中國呈獻：快樂之泉多巴胺》藝術畫冊榮獲「最佳市場推廣項目──刊物（業界）」金獎。是次獲獎畫冊由金沙中國團隊聯同本澳策展機構ARTICROSS及設計團隊UNTITLED MACAO編撰，作為公司於去年7月至10月期間呈獻的「藝文薈澳：澳門國際藝術雙年展2025」特展《快樂之泉多巴胺》及平行展《無界藝象：國際當代藝術展》之重要文本紀錄。

其中，特展《快樂之泉多巴胺》匯聚九位來自亞洲、歐洲及美洲的國際知名當代藝術家，包括Craig & Karl、李綺婷、GRAFFLEX、陸曦、Ilya Milstein、Jun Oson、Jonni Cheatwood 及周松，聯乘經典品牌《芝麻街》呈獻14件專為澳門委約創作的藝術佳作，並於澳門威尼斯人^®展出；透過多巴胺的絢麗色彩美學，重新演繹《芝麻街》的歡樂與正向精神。而同期於金沙藝廊舉行的平行展《無界藝象：國際當代藝術展》則延伸探索藝術與世界感知之間的無垠疆界，由其中六位特展藝術家帶來逾60多件作品，橫跨繪畫、雕塑、裝置藝術、混合媒材等不同藝術媒介，引領觀眾重構對藝術、自我、與世界連結的想像。

兩項展覽一脈相承，從情感共鳴延伸至思想探索，為澳門呈獻一場兼具國際視野與人文關懷的藝術盛事，更向世界展現澳門高質量的策展實力與創新活力。為期三個月的展覽共吸引逾410萬人次參觀，充分展現展覽廣泛的吸引力。

是次獲獎的藝術畫冊完整收錄兩展的策展理念，以及九位海內外藝術家的創作思考、手稿與藝術脈絡。全書運用斑斕豐沛的色彩編排，透過文字與圖像凝練展覽精髓，細膩詮釋多巴胺美學的生命光彩，以及當代藝術回應時代、連結世界的深層意義。公司繼去年憑雙語圖冊《芳草尋源——圖説草堆街》榮獲同項殊榮後，今年再憑畫冊連續第二年蟬聯獎項，再次印證金沙中國悉力以巧思策劃高水準刊物，留存澳門文化藝術發展的珍貴印記。

為擴大展覽的影響力，《金沙中國呈獻：快樂之泉多巴胺》藝術畫冊已納入澳門公共圖書館永久館藏，並同步推出電子版，供世界各地讀者閱覽，感受澳門多元、豐厚的文化魅力。有關藝術畫冊電子版可透過以下連結瀏覽：https://l.ead.me/bgyN4z。

是次兩項金獎殊榮，充分肯定金沙中國多年來深耕非博彩元素、推動綜合旅遊休閒業多元發展的努力與成果。未來，金沙中國將繼續發揮企業資源，開創更多「旅遊+」跨界項目，攜手澳門政府及社會各界，豐富世界旅遊休閒中心內涵，為澳門經濟適度多元發展開拓更廣闊空間。

亞太旅遊協會金獎是亞太地區旅遊業最具權威性的國際獎項之一，獎項自1984年設立以來，表彰於策略實踐、創新成果及可持續發展等方面表現卓越的旅遊機構及項目，持續推動旅遊業高質量及可持續發展。

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

傳媒查詢：

金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected]              

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

Southeast Asia Leading Position Sustained; Market Share in China and Other Markets Rises Steadily

HONG KONG, Aug. 20, 2026 /PRNewswire/ -- J&T Global Express Limited ("J&T Express" or "J&T" or the "Company", stock code: 01519.HK), a global logistics service provider, today announced its Interim Results 2026 ("1H2026"). In 1H2026, the Company sustained steady development across its global business, providing solid momentum for overall business growth. Revenue reached US$7.67 billion, up 39.5% YoY. Revenue from express delivery services reached US$7.46 billion, up 39.6% YoY.

In 1H2026, the Company's total parcel volume reached 17.50 billion, up 25.1% YoY. In the second quarter, the Company's global average daily parcel volume exceeded 100 million for the first time, marking a new stage in the Company's fulfillment scale. Alongside scale expansion, the Company's profitability improved significantly. Adjusted net profit reached US$350.6 million, up 124.3% YoY, while adjusted EBIT reached US$433.6 million, up 121.7% YoY. The Group's adjusted EBIT per parcel also achieved notable growth, reflecting the benefits of economies of scale, cost control and customer structure optimization. In June 2026, the Company was included as a constituent stock of the Hang Seng Index, officially becoming a Hong Kong blue-chip company.

Dylan Tey, Chief Financial Officer of J&T Express, said: "In 1H2026, the Company expanded its revenue base and significantly strengthened profitability. The Group's adjusted EBIT per parcel reached US$0.025, up 77% YoY. The improvement in both revenue and profitability was driven by parcel volume growth supported by the globalization of e-commerce and diversified customer expansion, as well as continued improvements in service quality and operational efficiency. In 1H2026, the Group's operating cash flow reached US$635.5 million, up 50.9% YoY. As of the end of the reporting period, the Group maintained ample cash resources, with cash and cash equivalents, restricted cash and bank wealth management products totaling US$2.91 billion. We have always placed great emphasis on shareholder returns. In 1H2026, the Company completed the repurchase of 99.318 million shares, and on June 25 announced an increase in the size of its new share repurchase plan to HK$2.0 billion."

Market Share in Southeast Asia Rises Further; Leadership Position Remains Solid

Southeast Asia was an important driver of J&T's business growth in the first half of the year. In 1H2026, parcel volume in Southeast Asia reached 5.52 billion, up 71.2% YoY, with average daily parcel volume reaching 30.50 million. According to Frost & Sullivan, by parcel volume, the Company has ranked first in the Southeast Asian market for six consecutive years since 2020, with its leading position further strengthened.

The Company continued to capture opportunities arising from regional e-commerce and social commerce development. Leveraging its extensive network coverage, stable fulfillment capabilities and localized operating experience, J&T strengthened its regional service capabilities. As of June 30, 2026, the Company operated 127 sorting centers in Southeast Asia, with the number of automated sorting lines increasing by 11 from the end of 2025 to 75, providing strong support for regional parcel volume growth and service quality improvement. At the same time, the Company advanced the development of last-mile automation capabilities in Southeast Asia by equipping outlets with automated equipment, improving frontline efficiency and reducing overall operating costs.

The Company also actively expanded its non-platform business, covering diversified customer groups such as social commerce merchants, online businesses of chain brands, enterprise customers and individual parcel customers. It also promoted time-definite products such as same-day and next-day delivery for non-platform customers, improved door-to-door pickup coverage, upgraded outlet appearances, and enhanced courier service evaluation mechanisms to support more diversified fulfillment scenarios.

China Market Grows Steadily amid High-Quality Industry Development

In China, the industry has entered a high-quality development cycle, while J&T has focused on service quality, network stability and end-to-end cost optimization, with market share extending its gains. In 1H2026, parcel volume in China reached 11.615 billion, up 9.6% YoY, with average daily parcel volume reaching 64.20 million. According to Frost & Sullivan data, by parcel volume, the Company's market share in China increased to 11.6%, up 0.5 percentage points YoY.

The Company continued to strengthen its network capabilities, helping network partners improve their market expansion, customer service and overall operating capabilities. Through enhanced value-added services such as door-to-door service, dedicated customer service, priority service channels and the "Tuyouda" service, the Company improved service adaptability and response efficiency. In terms of business structure, the Company actively expanded diversified customer groups, including brand customers, individual parcel customers and industrial belt customers, and deepened its presence in key industrial belts such as footwear, apparel and women's fashion, providing customized solutions for merchants' core needs such as packaging protection and pickup timeliness.

In smart logistics, the Company expanded the deployment of unmanned delivery vehicles in China. As of June 30, 2026, more than 1,900 unmanned delivery vehicles had been deployed across the network, up 87% from the end of 2025. The Company also deepened the application of AI to further improve service experience and operating efficiency.

Other Markets Maintain Rapid Growth; Localized Partnerships Continue to Deepen

In Other Markets, the Company maintained rapid business growth. In 1H2026, parcel volume in Other Markets reached 365 million, up 119.9% YoY. Frost & Sullivan data shows that, by parcel volume, the Company's market share in Other Markets increased from 6.2% in the first half of 2025 to 8.9%.

The Company seized e-commerce development and cross-border logistics opportunities in regions such as Latin America and the Middle East, deepening cooperation with global e-commerce platforms and short-video livestreaming platforms including TikTok, SHEIN, Temu, Kwai and AliExpress. It also strengthened its cooperation with local e-commerce platforms, deepening cooperation with Mercado Libre in Brazil and Mexico and continuing to reinforce partnerships with Noon and Salla in the Middle East, further expanding its local business opportunities.

As of June 30, 2026, the Company had 52 sorting centers and more than 2,700 outlets in Other Markets, and had deployed 14 automated sorting lines. The Company actively explored flexible last-mile fulfillment models tailored to the needs of different markets, working with market players possessing local resources and operational experience to address fulfillment challenges in complex market environments. At the same time, by leveraging mature experience accumulated in China and Southeast Asia, J&T improved local network coverage, operating efficiency and service quality to better capture opportunities arising from e-commerce development and growing express delivery demand in regions such as Latin America.

From the perspective of global network layout and transportation capabilities, in the first half of 2026, the Company operated 260 sorting centers globally, had approximately 19,800 outlets, 435 automated sorting lines and approximately 13,380 line-haul vehicles, including approximately 8,500 self-owned line-haul vehicles. To meet customer needs, the Company actively expanded service scenarios including cross-border e-commerce, brand customers, non-platform parcel business and fulfillment warehouses, extending its fulfillment service chain. The Company currently has a total of 272 warehouses worldwide, with a total area of over 1.01 million square meters.

Charles Hou, Group Vice President of J&T Express, said: "In 1H2026, J&T achieved strong growth in global parcel volume. The scale benefits and fulfillment capabilities of J&T's global network continued to strengthen, with profitability also improving. We are committed to strengthening operating quality and efficiency to drive steady business scale expansion. In the second quarter, the Company's global average daily parcel volume exceeded 100 million for the first time. Looking ahead, we will tailor our approach to the development stage of each market, stay guided by customer needs, continue to refine service quality, capture opportunities from global expansion, and drive steady, long-term growth across our global business."